title: [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].
abstract: OBJECTIVE
  To discuss the clinical and cytogenetic features of core binding factor (CBF) acute myeloid leukemia (AML) patients and the main factors that influence the prognosis.
  
  
  METHODS
  Totally 130 CBF AML patients were followed up and their clinical features, immunophenotype, chromosome karyotype, treatment regimen, overall survival (OS), and relapse-free survival (RFS) were analyzed.
  
  
  RESULTS
  The overall complete remission (CR) rate was 96.1%, among which the CR rate after the first treatment course was 77.2%. The overall median OS was 51.64 (0.26-132.5) months, while the median RFS did not reach 1.18-96.62 months. The 3-year OS was 50% and the 5-year OS was 41%; the 3-year RFS was 59% and the 5-year RFS was 54%. Patients who were over 45 years and those with chromosome karyotype of 9q- tended to have poorer prognosis. During the consolidating chemotherapy, patients who had received two or more courses of intermediate-dose Ara-C therapy had better prognosis and longer survival. AML patients with inv (16) /t (16; 16) had a significantly higher OS than those with t (8; 21) (P = 0.046), while the RFS showed an opposite finding (P = 0.038).
  
  
  CONCLUSIONS
  Age, chromosomal karyotype, and consolidating chemotherapy are the main factors that influence the survival and prognosis of CBF AML patients. Two or more courses of intermediate-dose Ara-C during consolidating chemotherapy can obviously prolong the OS and RFS of CBF AML patients. AML patients with a chromosomal karyotype of inv (16) /t (16; 16) have longer OS and better prognosis than those with t (8; 21).
authors.affiliation: Leukemia Diagnosis and Treatment Center, Institute of Hematology and Blood Disease Hospital, CAMS and PUMC, Tianjin 300020, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Ying-Chang
authors.initials: YC
authors.lastname: Mi
authors.forename: Bing-Cheng
authors.initials: BC
authors.lastname: Liu
authors.forename: Chun-Lin
authors.initials: CL
authors.lastname: Zhou
authors.forename: Dong
authors.initials: D
authors.lastname: Lin
authors.forename: Hui-Jun
authors.initials: HJ
authors.lastname: Wang
authors.forename: Xu-Ping
authors.initials: XP
authors.lastname: Liu
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Li
authors.forename: Shou-Geng
authors.initials: SG
authors.lastname: Bian
authors.forename: Jian-Xiang
authors.initials: JX
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D050660:Core Binding Factors; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D050660:Core Binding Factors